特澤魯單抗
 | 此條目可參照英語維基百科相應條目來擴充。 (2025年1月14日) |
 特澤魯單抗抑制 TSLP 信號傳導的結構基礎 (PDB 5J13)[1] | |
| 單株抗體 | |
|---|---|
| 種類 | 完整抗體 |
| 目標 | 胸腺基質淋巴細胞生成素 (TSLP) |
| 臨床資料 | |
| 商品名 | Tezspire |
| 其他名稱 | MEDI9929, AMG 157, tezepelumab-ekko |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a622010 |
| 核准狀況 | |
| 給藥途徑 | 皮下注射 |
| ATC碼 | |
| 法律規範狀態 | |
| 法律規範 |
|
| 識別資訊 | |
| CAS號 | 1572943-04-4 |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化學資訊 | |
| 化學式 | C6400H9844N1732O1992S52 |
| 摩爾質量 | 144,590.40 g·mol−1 |
特澤魯單抗（INN：tezepelumab）用於治療哮喘[9] [10]。特別適用其他藥物無法控制的嚴重哮喘，患者需12歲以上[10]。每4周皮下注射一次[10]。
最常見的副作用包括關節痛和喉嚨痛[10]。其他副作用包括可能有過敏反應[9]。雖然無證據顯示孕期使用對胎兒有害，但研究仍不充分[9]。它是一種單株抗體，可阻斷胸腺基質淋巴細胞生成素（TSLP），並減少呼吸道的發炎反應[9] [10]。
特澤魯單抗於2021年及2022年在美國及歐洲取得醫療使用許可[9] [10]。雖然已在英國取得許可，但截至2022年整尚未上市[11]
參考文獻
[編輯]- ^ Verstraete K, Peelman F, Braun H, Lopez J, Van Rompaey D, Dansercoer A, et al. Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma. Nature Communications. April 2017, 8 (1): 14937. Bibcode:2017NatCo...814937V. PMC 5382266
. PMID 28368013. doi:10.1038/ncomms14937.
- ^ Tezspire Product information. Health Canada. 25 April 2012 [1 October 2022]. （原始內容存檔於1 October 2022）.
- ^ Summary Basis of Decision - Tezspire. Health Canada. 23 October 2014 [24 January 2023]. （原始內容存檔於24 January 2023）.
- ^ Details for: Tezspire. Health Canada. 19 October 2022 [3 March 2024].
- ^ Tezspire- tezepelumab-ekko injection, solution. DailyMed. [24 December 2021]. （原始內容存檔於25 December 2021）.
- ^ Tezspire (tezepelumab) approved in the US for severe asthma. AstraZeneca (新聞稿). 17 December 2021 [17 December 2021]. （原始內容存檔於18 December 2021）.
- ^ Tezspire EPAR. European Medicines Agency. 19 July 2022 [21 September 2022]. （原始內容存檔於22 September 2022）. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ Tezspire Product information. Union Register of medicinal products. 12 December 2022 [3 March 2023]. （原始內容存檔於27 October 2022）.
- ^ 9.0 9.1 9.2 9.3 9.4 Tezspire- tezepelumab-ekko injection, solution. DailyMed. [24 December 2021]. （原始內容存檔於25 December 2021）.
- ^ 10.0 10.1 10.2 10.3 10.4 10.5 Tezspire EPAR. European Medicines Agency. 19 July 2022 [21 September 2022]. （原始內容存檔於22 September 2022）.
- ^ Tezepelumab. SPS - Specialist Pharmacy Service. 16 March 2018 [24 October 2022]. （原始內容存檔於6 March 2022）.
外部連結
[編輯]- Clinical trial number NCT02054130 for "Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma" at ClinicalTrials.gov
- Clinical trial number NCT03347279 for "Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma (NAVIGATOR)" at ClinicalTrials.gov
